Acute Leukemia Forum 2021 

April 7, 2021 – April 8, 2021

Complimentary CME Event

For 25 years, the Acute Leukemia Forum has provided a unique platform that enables the world’s leading experts to share and discuss the latest research and clinical advances impacting the treatment and management of patients with acute leukemia and myelodysplasia. The program focuses on addressing the educational needs of hematology/oncology healthcare professionals treating or managing patients with these malignancies.


Dear Colleagues:

It is our pleasure to welcome you to this virtual conference, Acute Leukemia Forum 2021, our 25th consecutive annual meeting. This important innovative CME/CE initiative will take you on a unique learning journey, which begins when you enter the Virtual Conference Center.

The comprehensive agenda held over two days includes six sessions:

  • Advances in Myelodysplasia
  • Novel Strategies in ALL
  • Basic Biology
  • AML - Therapy of Induction, Post-remission and Relapse
  • Bone Marrow Transplantation
  • Supportive Care

And will end with our keynote Ernest Beutler Memorial Lecture

Our internationally renowned faculty will engage you as you take a seat in the Live Theater and will, following each of the presentations, leave ample time for your questions to be addressed.

As with any live conference, you will find additional opportunities to interact with your colleagues beyond the sessions. We invite you to explore the Virtual Poster Hall, network in the Lounge, and visit the Exhibit Hall.

Each of the presentations will be prerecorded and if you miss one or just as a refresher, you will be able to go back to the educational theater and watch it again. Some, if not all of the slides, will be available for downloading as PDFs.

Once again, we look forward to welcoming you to this important educational activity.


Robert Harrington signature


Martin S. Tallman, MD



9.25 CME/CE 


This educational activity is specifically designed for hematologists, hematologists/oncologists, and the hematology/oncology healthcare team.


After attending this meeting, participants will be able to: [list] [item]Evaluate updates in the treatment and management of myelodysplasia [item]Appraise the clinical potential of novel strategies in the management of various subsets of ALL [item]Assess recent advances in the biology and treatment of AML [item]Recognize critical updates in bone marrow transplantation and management of GVHD [item]Apply evidence-based strategies to integrate progress into clinical practice [/list]